Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/22495
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wurtman, Richard J. | - |
dc.contributor.author | Sakamoto, Toshimasa | - |
dc.date.accessioned | 2021-10-27T07:31:28Z | - |
dc.date.available | 2021-10-27T07:31:28Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | Wurtman, R. J. vd. (2009). "Use of phosphatide precursors to promote synaptogenesis". Annual Review of Nutrition, 29, 59-87. | en_US |
dc.identifier.issn | 0199-9885 | - |
dc.identifier.uri | https://doi.org/10.1146/annurev-nutr-080508-141059 | - |
dc.identifier.uri | https://www.annualreviews.org/doi/10.1146/annurev-nutr-080508-141059 | - |
dc.identifier.uri | http://hdl.handle.net/11452/22495 | - |
dc.description.abstract | New brain synapses form when a postsynaptic structure, the dendritic spine, interacts with a presynaptic terminal. Brain synapses and dendritic spines, membrane-rich structures, are depleted in Alzheimer's disease,as are some circulating compounds needed for synthesizing phosphatides, the major constituents of synaptic membranes. Animals given three of these compounds, all nutrients-uridine, the omega-3 polyunsaturated fatty acid docosahexaenoic acid, and choline-develop increased levels of brain phosphatides and of proteins that are concentrated within synaptic membranes (e.g., PSD-95, synapsin-1), improved cognition, and enhanced neurotransmitter release. The nutrients work by increasing the substrate-saturation of low-affinity enzymes that synthesize the phosphatides. Moreover, uridine and its nucleotide metabolites activate brain P2Y receptors, which control neuronal differentiation and synaptic protein synthesis. A preparation containing these compounds is being tested for treating Alzheimer's disease. | en_US |
dc.description.sponsorship | United States Department of Health & Human Services National Institutes of Health (NIH) - USA | en_US |
dc.description.sponsorship | Center for Brain Sciences and Metabolism Charitable Trust | en_US |
dc.language.iso | en | en_US |
dc.publisher | Annual Reviews | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Cognition | en_US |
dc.subject | Alzheimer's disease | en_US |
dc.subject | Phosphatide | en_US |
dc.subject | Dendritic spine | en_US |
dc.subject | Synaptic membrane | en_US |
dc.subject | P2Y receptors | en_US |
dc.subject | Fatty-acid-composition | en_US |
dc.subject | Ctp-phosphocholine cytidylyltransferase | en_US |
dc.subject | Plasma choline concentrations | en_US |
dc.subject | Plus docosahexaenoic acid | en_US |
dc.subject | Rat sympathetic neurons | en_US |
dc.subject | Brain-barrier transport | en_US |
dc.subject | Alpha-linolenic acid | en_US |
dc.subject | Hamster ovary cells | en_US |
dc.subject | Cdp-choline | en_US |
dc.subject | Alzheimers-disease | en_US |
dc.subject | Nutrition & dietetics | en_US |
dc.subject | Animalia | en_US |
dc.subject.mesh | Alzheimer disease | en_US |
dc.subject.mesh | Choline | en_US |
dc.subject.mesh | Docosahexaenoic acids | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Phospholipids | en_US |
dc.subject.mesh | Prodrugs | en_US |
dc.subject.mesh | Synapses | en_US |
dc.subject.mesh | Synaptic transmission | en_US |
dc.subject.mesh | Uridine | en_US |
dc.title | Use of phosphatide precursors to promote synaptogenesis | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000270118600004 | tr_TR |
dc.identifier.scopus | 2-s2.0-67749111670 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi. | tr_TR |
dc.contributor.orcid | 0000-0003-2918-5064 | tr_TR |
dc.identifier.startpage | 59 | tr_TR |
dc.identifier.endpage | 87 | tr_TR |
dc.identifier.volume | 29 | tr_TR |
dc.relation.journal | Annual Review of Nutrition | en_US |
dc.contributor.buuauthor | Cansev, Mehmet | - |
dc.contributor.buuauthor | Ulus, İsmail Hakkı | - |
dc.contributor.researcherid | D-5340-2015 | tr_TR |
dc.contributor.researcherid | M-9071-2019 | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.identifier.pubmed | 19400698 | tr_TR |
dc.subject.wos | Nutrition & dietetics | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.wos | BKCIS | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | Pubmed | en_US |
dc.wos.quartile | Q1 | en_US |
dc.contributor.scopusid | 8872816100 | tr_TR |
dc.contributor.scopusid | 7004271086 | tr_TR |
dc.subject.scopus | Choline Phosphate Cytidylyltransferase; Phosphatidylcholines; Citicoline | en_US |
dc.subject.emtree | Choline | en_US |
dc.subject.emtree | Cyanocobalamin | en_US |
dc.subject.emtree | Docosahexaenoic acid | en_US |
dc.subject.emtree | Folic acid | en_US |
dc.subject.emtree | Phospholipid | en_US |
dc.subject.emtree | Postsynaptic density protein 95 | en_US |
dc.subject.emtree | Purinergic P2Y receptor | en_US |
dc.subject.emtree | Pyridoxine | en_US |
dc.subject.emtree | Souvenaid | en_US |
dc.subject.emtree | Synapsin I | en_US |
dc.subject.emtree | Unclassified drug | en_US |
dc.subject.emtree | Uridine | en_US |
dc.subject.emtree | Alzheimer disease | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Cognition | en_US |
dc.subject.emtree | Dendritic spine | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Nerve ending | en_US |
dc.subject.emtree | Neurotransmitter release | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Phospholipid synthesis | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Review | en_US |
dc.subject.emtree | Synapse | en_US |
dc.subject.emtree | Synaptic membrane | en_US |
dc.subject.emtree | Synaptogenesis | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.